The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3′,3′-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain

Virology Journal

Volumn 5, Issue , 2008, Pages

  DaFonseca, Sandrina ^a   Coric, Pascale ^b   Gay, Bernard ^c,d   Hong, Saw See ^a   Bouaziz, Serge ^b   Boulanger, Pierre ^a,c,d  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIV MONTPELLIER   (France)

^d HOSPICES CIVILS DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVIRIMAT; GAG PROTEIN; VIF PROTEIN; 3-O-(3',3'-DIMETHYLSUCCINYL)BETULINIC ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; SUCCINIC ACID DERIVATIVE; TRITERPENE; VIF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; ZINC;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PROTEIN EXPRESSION; VIRUS PARTICLE; ANIMAL; CELL LINE; DRUG EFFECT; GENETICS; METABOLISM; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; VIRION; VIRUS ASSEMBLY;

HEXAPODA; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; ANTI-HIV AGENTS; CELL LINE; HIV-1; PROTEIN STRUCTURE, TERTIARY; SUCCINATES; TRITERPENES; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRION; VIRUS ASSEMBLY; ZINC;

EID: 58749088531     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-5-162     Document Type: Article

References (76)

1. Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation. T Kanamoto Y Kashiwada K Kanbara K Gotoh M Yoshimori T Goto K Sano H Nakashima, Antimicrob Agents Chemother 2001 45 1225 1230 11257038
2. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. F Li R Goila-Gaur K Salzwedel NR Kilgore M Reddick C Matallana A Castillo D Zoumplis DE Martin JM Orenstein GP Allaway EO Freed CT Wild, Proc Natl Acad Sci USA 2003 100 13555 13560 14573704
3. Determinants of activity of the HIV-1 maturation inhibitor PA-457. F Li D Zoumplis C Matallana NR Kilgore M Reddick AS Yunus CS Adamson K Salzwedel DE Martin GP Allaway EO Freed CT Wild, Virology 2006 356 217 224 16930665
4. The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3′,3′-dimethylsuccinyl}-betulinic acid. J Zhou CH Chen C Aiken, Retrovirology 2004 1 15 15225375
5. Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. Y Kashiwada F Hashimoto LM Cosentino CH Chen PE Garrett KH Lee, J Med Chem 1996 39 1016 1017 8676334
6. Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J Zhou X Yuan D Dismuke BM Forshey C Lundquist KH Lee C Aiken CH Chen, J Virol 2004 78 922 929 14694123
7. Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. X Zhou LJ Parent JW Wills MD Resh, J Virol 1994 68 2556 2569 8139035
8. Betulinic acid derivatives as HIV-1 antivirals. C Aiken CH Chen, Trends Mol Med 2005 11 31 36 15649820
9. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. S Pettit MD Moody RS Wehbie AH Kaplan PV Nantermet CA Klein R Swanstrom, J Virol 1994 68 8017 8027 7966591
10. Proteolytic processing of the p2/nucleocapsid cleavage site is critical for human immunodeficiency virus type 1 RNA dimer maturation. M Shehu-Xhilaga H-G Kräusslich S Pettit R Swanstrom JY Lee JA Marshall SM Crowe J Mak, J Virol 2001 75 9156 9164 11533179
11. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). CS Adamson SD Ablan I Boeras R Goila-Gaur F Soheilian K Nagashima F Li K Salzwedel M Sakalian CT Wild EO Freed, J Virol 2006 80 10957 10971 16956950
12. 3-O-(3′,3′-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro. M Sakalian CP McMurtrey FJ Deeg CW Maloy F Li CT Wild K Salzwedel, J Virol 2006 80 5716 5722 16731910
13. Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles. J Zhou L Huang DL Hachey CH Chen C Aiken, J Biol Chem 2005 280 42149 42155 16251182
14. The 3-O-(3′,3′-dimethylsuccinyl) derivative of betulinic acid (DSB) inhibits the assembly of virus-like particles in HIV-1 Gag precursor-expressing cells. S DaFonseca A Blommaert P Coric SS Hong S Bouaziz P Boulanger, Antiviral Ther 2007 12 8 1185 1203
15. 3-O-glutaryl-dihydrobetulin and related monoacyl derivatives as potent anti-HIV agents. Y Kashiwada M Sekiya Y Ikeshiro T Jujioka NR Kilgore CT Wild GP Allaway K-H Lee, Bioorg Med Chem Lett 2004 14 5851 5853 15501054
16. Expression and extracellular release of human immunodeficiency virus type 1 Gag precursors by recombinant baculovirus-infected cells. M Royer SS Hong B Gay M Cerutti P Boulanger, J Virol 1992 66 3230 3235 1560545
17. Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564. X Yuan L Huang P Ho C Labranche CH Chen, Virology 2004 324 525 530 15207637
18. Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41. B Labrosse O Pleskoff N Sol C Jones Y Henin M Alizon, J Virol 1997 71 8230 8236 9343174
19. Human immunodeficiency virus type 1 assembly, release and maturation. CS Adamson EO Freed, Adv Pharmacol 2007 55 347 387 17586320
20. A putative alpha-helical structure which overlaps the capsid-p2 boundary in the human immunodeficiency virus type 1 Gag precursor is crucial for viral particle assembly. MA Accola S Höglund HG Göttlinger, J Virol 1998 72 2072 2078 9499062
21. Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 gag precursor. F Bachand XJ Yao M Hrimech N Rougeau EA Cohen, J Biol Chem 1999 274 9083 9091 10085158
22. Biochemical analyses of the interactions between human immunodeficiency virus type 1 Vpr and p6(Gag). Y Jenkins O Pornillos RL Rich DG Myszka WI Sundquist MH Malim, J Virol 2001 75 10537 10542 11581428
23. Human immunodeficiency virus type 1 Vpr protein is incorporated into the virion in significantly smaller amounts than Gag and is phosphorylated in infected cells. B Müller U Tessmer U Schubert H-G Kräusslich, J Virol 2000 74 9727 9731 11000245
24. Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors: co-encapsidation and interference with viral protease-mediated Gag processing. M Bardy B Gay S Pébernard N Chazal M Courcoul R Vigne E Decroly P Boulanger, J Gen Virol 2001 82 2719 2733 11602784
25. High level expression of human immunodeficiency virus type-1 Vif inhibits viral infectivity by modulating proteolytic processing of the Gag precursor at the p2/nucleocapsid processing site. H Akari M Fujita S Kao MA Khan M Shehu-Xhilaga A Adachi K Strebel, J Biol Chem 2004 279 12355 12362 14722068
26. Three-dimensional structure of HIV-1 VIF constructed by comparative modeling and the function characterization analyzed by molecular dynamics simulation. W Lv Z Liu H Jin X Yu L Zhang L Zhang, Org Biomol Chem 2007 5 617 626 17285170
27. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Z Xiao E Ehrlich Y Yu K Luo T Wang C Tian Y X-F, Virology 2006 349 290 299 16530799
28. Characterization of a novel Cullin5 binding domain in HIV-1 Vif. Z Xiao Y Xiong W Zhang L Tan E Ehrlich D Guo X-F Yu, J Mol Biol 2007 373 541 550 17869271
29. The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. N Srinivasakumar N Chazal C Helga-Maria S Prasad M-L Hammarskjöld D Rekosh, J Virol 1997 71 5841 5848 9223473
30. Human immunodeficiency virus type 1 Nef associates with lipid rafts to downmodulate cell surface CD4 and class I major histocompatibility complex expression and to increase infectivity. M Alexander Y-C Bor KS Ravichandra M-L Hammarskjöld D Rekosh, J Virol 2004 78 1685 1696 14747534
31. Assembling the human immunodeficiency virus type 1. A Cimarelli J-L Darlix, Cell Mol Life Sci 2002 59 1166 1184 12222963
32. HIV-1 Gag proteins: diverse functions in the virus life cycle. EO Freed, Virology 1998 251 1 15 9813197
33. Retrovirus budding. DG Demirov EO Freed, Virus Res 2004 106 87 102 15567490
34. Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. EO Freed MA Martin, J Virol 1996 70 341 351 8523546
35. The cell biology of HIV-1 and other retroviruses. EO Freed AJ Mouland, Retrovirology 2006 3 77 17083721
36. Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail. T Murakami EO Freed, J Virol 2000 74 3548 3554 10729129
37. Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. C Aiken D Trono, J Virol 1995 69 5048 5056 7541845
38. Disassembly of human immunodeficiency virus type 1 cores in vitro reveals association of Nef with the subviral ribonucleoprotein complex. BM Forshey C Aiken, J Virol 2003 77 4409 4414 12634398
39. Virion incorporation of human immunodeficiency virus type 1 Nef is mediated by a bipartite membrane-targeting signal: analysis of its role in enhancement of viral infectivity. R Welker M Harris B Cardel HG Krausslich, J Virol 1998 72 8833 8840 9765428
40. Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase. R Welker H Kottler HR Kalbitzer HG Krausslich, Virology 1996 219 228 236 8623533
41. Mutagenesis of the putative alpha-helical domain of the Vpr protein of human immunodeficiency virus type 1: effect on stability and virion incorporation. S Mahalingam SA Khan R Murali MA Jabbar CE Monken RG Collman A Srinivasan, Proc Natl Acad Sci USA 1995 92 3794 3798 7731985
42. NMR structure of the HIV-1 regulatory protein Vpr. N Morellet S Bouaziz P Petitjean BP Roques, J Mol Biol 2003 327 215 227 12614620
43. Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr. SP Singh B Tomkowicz D Lai M Cartas S Mahalingam VS Kalyanaraman R Murali A Srinivasan, J Virol 2000 74 10650 10657 11044109
44. Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation. XJ Yao RA Subbramanian N Rougeau F Boisvert D Bergeron EA Cohen, J Virol 1995 69 7032 7044 7474123
45. A conserved dileucine-containing motif in p6(gag) governs the particle association of Vpx and Vpr of simian immunodeficiency viruses SIV(mac) and SIV(agm). MA Accola AA Bukovsky MS Jones HG Göttlinger, J Virol 1999 73 9992 9999 10559313
46. A leucine triplet repeat sequence (LXX)4 in p6 gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. YL Lu RP Bennett JW Wills R Gorelick L Ratner, J Virol 1995 69 6873 6879 7474102
47. Interaction with the p6 domain of the Gag precursor mediates incorporation into virions of Vpr and Vpx proteins from primate lentiviruses. L Selig J-C Pages V Tanchou S Prévéral C Berlioz-Torrent LX Liu L Erdtmann J-L Darlix R Benarous S Benichou, J Virol 1999 73 592 600 9847364
48. Proline 35 of human immunodeficiency virus type 1 (HIV-1) Vpr regulates the integrity of the N-terminal helix and the incorporation of Vpr into virus particles and supports the replication of R5-tropic HIV-1 in human lymphoid tissue ex vivo. J Votteler N Studtrucker S Sörgel J Münch E Rücker F Kirchhoff B Schick P Henklein T Fossen K Bruns A Sharma V Wray U Schubert, J Virol 2007 81 9572 9576 17553868
49. Human immunodeficiency virus type 1 Vif protein binds to the Pr55GAG precursor. M Bouyac M Courcoul G Bertoia Y Baudat D Gabuzda D Blanc N Chazal P Boulanger R Vigne B Spire, J Virol 1997 71 9358 9365 9371595
50. Interaction and co-encapsidation of HIV-1 Vif and Gag recombinant proteins. I Huvent SS Hong C Fournier B Gay J Tournier C Carriere M Courcoul R Vigne B Spire P Boulanger, J Gen Virol 1998 79 1069 1081 9603321
51. Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production. L Baraz A Friedler I Blumenzweig O Nussinuv N Chen M Steinitz C Gilon M Kotler, FEBS Letters 1998 441 419 426 9891983
52. Human immunodeficiency virus type 1 Vif-mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. AM Borman C Quillent P Charneau C Dauguet F Clavel, J Virol 1995 69 2058 2067 7884851
53. Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. M Dettenhofer S Cen BA Carlson L Kleiman X-F Yu, J Virol 2000 74 8938 8945 10982337
54. Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains. J Goncalves B Shi X Yang D Gabuzda, J Virol 1995 69 7196 7204 7474141
55. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. S Kao MA Khan E Miyagi R Plishka A Buckler-White K Strebel, J Virol 2003 77 11398 11407 14557625
56. Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 vif protein. S Karczewski K Strebel, J Virol 1996 70 494 507 8523563
57. The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures. H Liu X Wu M Newman GM Shaw BH Hahn JC Kappes, J Virol 1995 69 7630 7638 7494271
58. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. A Mehle J Goncalves M Santa-Marta M McPike D Gabuzda, Genes Dev 2004 18 2861 2866 15574592
59. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. A Mehle B Strack P Ancuta C Zhang M McPike D Gabuzda, J Biol Chem 2004 279 7792 7798 14672928
60. Identification of an APOBEC3G binding site in HIV-1 Vif and inhibitors of Vif-APOBEC3G binding. A Mehle H Wilson C Zhang AJ Brazier M McPike E Pery D Gabuzda, J Virol 2007 81 13235 13241 17898068
61. Comparison of Vif sequences from diverse geographical isolates of HIV type 1 and SIV(cpz) identifies substitutions common to subtype C isolates and extensive variation in a proposed nuclear transport inhibition signal. EB Stephens DK Singh E Pacyniak C McCormick, AIDS Res Hum Retroviruses 2001 17 169 177 11177396
62. Cysteine residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity. X-Y Ma P Sova W Chao DJ Volsky, J Virol 1994 68 1714 1720 8107232
63. Mutational analysis of the human immunodeficiency virus type 1 Vif protein. JHM Simon AM Sheehy EA Carpenter RAM Fouchier MH Malim, J Virol 1999 73 2675 2681 10074113
64. Morphopoietic determinants of HIV-1 GAG particles assembled in baculovirus-infected cells. B Gay J Tournier N Chazal C Carrière P Boulanger, Virology 1998 247 160 169 9705909
65. Functional domains of HIV-1 gag-polyprotein expressed in baculovirus-infected cells. M Royer M Cerutti B Gay SS Hong G Devauchelle P Boulanger, Virology 1991 184 417 422 1871977
66. Intracellular trafficking of HIV-1 Gag: how Gag interacts with cell membranes and makes viral particles. MD Resh, AIDS Rev 2005 7 84 91 16092502
67. Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body. A Ono EO Freed, J Virol 2004 78 1552 1563 14722309
68. HIV-1 egress is gated through late endosomal membranes. S Nydegger M Foti A Derdowski P Spearman M Thali, Traffic 2003 4 902 910 14617353
69. Visualization of retroviral replication in living cells reveals budding into multivesicuar bodies. NM Sherer MJ Lehmann LF Jimenez-Soto A Ingmundson SM Horner G Cicchetti PG Allen M Pypaert JM Cunningham W Mothes, Traffic 2003 4 785 801 14617360
70. Sequence requirement for encapsidation of deletion mutants and chimeras of human immunodeficiency virus type 1 Gag precursor into retrovirus-like particles. C Carrière B Gay N Chazal N Morin P Boulanger, J Virol 1995 69 2366 2377 7884882
71. Phenotypic characterization of insertion mutants of the human immunodeficiency virus type 1 Gag precursor expressed in recombinant baculovirus-infected cells. N Chazal C Carrière B Gay P Boulanger, J Virol 1994 68 111 122 8254720
72. Analysis of HIV-1 Vpr determinants responsible for cell growth arrest in Saccharomyces cerevisiae. XJ Yao N Rougeau G Duisit J Lemay EA Cohen, Retrovirology 2004 1 21 15312229
73. RNA is a structural element in retrovirus particles. D Muriaux J Mirro D Harvin A Rein, Proc Natl Acad Sci USA 2001 98 5246 5251 11320254
74. H-EED, the product of the human homolog of the murine eed gene, binds to the matrix protein of HIV-1. R Peytavi SS Hong B Gay A Dupuy d'Angeac L Selig S Bénichou R Benarous P Boulanger, J Biol Chem 1999 274 1635 1645 9880543
75. The tyrosine kinases Fyn and Hck favor the recruitment of tyrosine-phosphorylated APOBEC3G into vif-defective HIV-1 particles. M Douaisi S Dussart M Courcoul G Bessou EC Lerner E Decroly R Vigne, Biochem Biophys Res Commun 2005 329 917 924 15752743
76. The Human Polycomb Group EED Protein Interacts with the Integrase of Human Immunodeficiency Virus Type 1. S Violot SS Hong D Rakotobe C Petit B Gay K Moreau G Billaud S Priet J Sire O Schwartz JF Mouscadet P Boulanger, J Virol 2003 77 12507 12522 14610174